Compare · NVO vs PBM
NVO vs PBM
Side-by-side comparison of Novo Nordisk A/S (NVO) and Psyence Biomedical Ltd. (PBM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PBM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.10B, about 27405.8x PBM ($7.2M).
- Over the past year, NVO is down 43.0% and PBM is down 88.2% - NVO leads by 45.2 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for PBM).
- NVO has more recent analyst coverage (25 ratings vs 0 for PBM).
- Company
- Novo Nordisk A/S
- Psyence Biomedical Ltd.
- Price
- $43.91+0.06%
- $3.25-2.40%
- Market cap
- $196.10B
- $7.2M
- 1M return
- -4.14%
- -36.27%
- 1Y return
- -43.00%
- -88.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PBM
- SEC Form 6-K filed by Psyence Biomedical Ltd.
- Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
- SEC Form 6-K filed by Psyence Biomedical Ltd.
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
- SEC Form 6-K filed by Psyence Biomedical Ltd.
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
- SEC Form 6-K filed by Psyence Biomedical Ltd.
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
- Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone